After its latest pipeline clear-out, Merck KGaA is no longer pursuing any clinical-stage cancer candidates obtained through ...

In a strikingly blunt briefing, a senior FDA official accused uniQure of pushing “distorted” data to mask a “failed” therapy ...

Zealand Pharma’s Roche-partnered amylin analogue demonstrated “placebo-like tolerability” and up to 10.7% mean weight loss at ...

Flagship Pioneering-backed Alltrna is once again laying off staff, this time reducing its workforce by 19 people. | Flagship ...

Venture capital firm Portal Innovations is planning to open a 30,000-square-foot science incubator in Salt Lake City while ...

With colon cancer deaths rising among younger adults and millions of eligible Americans skipping their colonoscopies, Guardant Health is taking its Shield blood test on the road in hopes of tackling ...

Tenaya leverages “human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) with high-throughput in vitro screening, imaging analysis, and machine learning algorithms” to identify new ...

The back-and-forth between the FDA and gene therapy developer uniQure is getting messier, with an agency spokesperson now denying the biotech’s claims about a sham trial request for the rare ...

Science has added a whole lot more cash to the bank, bringing in an impressive $230 million in its latest raise. | Science has added a whole lot more cash to the bank, bringing in an impressive $230 ...

Daiichi Sankyo’s European division is teaming up with German medtech Gaia to sell the latter company’s cardiovascular digital therapeutic lipodia. | Daiichi Sankyo’s European division is teaming up ...

The FDA has put a partial clinical hold on PepGen’s phase 2 mus | The FDA has put a partial clinical hold on PepGen’s phase 2 muscle wasting trial after reviewing preclinical data, continuing the stop ...

Two weeks after Teva touted promising long-term data for its Sanofi-partnered bowel disease drug, the Israeli pharma ...